OTC

ABC News' Dan Childs joins Bayer in external comms role

ABC News' Dan Childs joins Bayer in external comms role

By

Childs has worked at the network news division for more than a decade.

Five things for pharma marketers to know: Friday, January 19, 2018

Five things for pharma marketers to know: Friday, January 19, 2018

By

Biogen, UCB reportedly showing interest in Acorda acquisition; Kite Pharma and Pfizer to develop combo lymphoma therapy; hospitals to form generics nonprofit

CPG companies Nestlé and Kellogg court OTC

CPG companies Nestlé and Kellogg court OTC

By

A sea change may be afoot in OTC, with multiple healthcare businesses in play. Could consumer goods companies fill the void left by big pharma?

Five things for pharma marketers to know: Tuesday, December 26, 2017

Five things for pharma marketers to know: Tuesday, December 26, 2017

By

Roche to buy Ignyta for $1.7 billion; FDA OKs Valeant eye drop for OTC sale; Kmart settles prescription drug fraud allegations

Five things for pharma marketers to know: Tuesday, December 12, 2017

Five things for pharma marketers to know: Tuesday, December 12, 2017

By

FDA issues prescription drug promotion guidance; FDA approves first follow-on biologic of Lilly's Humalog; drugmakers allegedly hired nurses to promote drugs

Five things for pharma marketers to know: Wednesday, November 29, 2017

Five things for pharma marketers to know: Wednesday, November 29, 2017

By

U.K. to be first to sell OTC Viagra; Regeneron offers startup scientific expertise; docs more likely to get poor marks when they reject patient requests

How Lauren Schulz is shaping Dr. Reddy's OTC brands

How Lauren Schulz is shaping Dr. Reddy's OTC brands

By

She is director of OTC brand marketing at Dr. Reddy's Laboratories.

Agencies embrace health, in bid to diversify beyond pharma

Agencies embrace health, in bid to diversify beyond pharma

By

Healthcare networks instigated a broad set of changes in a grand embrace of non-pharma business that diversified revenue streams and took specialist agencies out of their comfort zones.

Excedrin acts fast to ease Mets fan's headache

Excedrin acts fast to ease Mets fan's headache

By

Excedrin jumped at the chance to help relieve an angry fan's headache when he missed opening day of the New York Mets season due to train delays.

Bayer creates 'everyday hero' campaign for aspirin

Bayer creates 'everyday hero' campaign for aspirin

By

The drugmaker worked with creative agency BBDO and PR firm Marina Maher Communications to develop the campaign.

Five things for pharma marketers to know: Monday, February 13, 2016

Five things for pharma marketers to know: Monday, February 13, 2016

By

Sanofi to sell five OTC drugs to Ipsen; Teva reports 33% revenue growth in Q4; Regeneron issued subpoena about support of nonprofits

Day 2 at JP Morgan: Change is coming, but which drugmakers will stay on top?

Day 2 at JP Morgan: Change is coming, but which drugmakers will stay on top?

By

J&J's CEO may be right. Customers of all kinds are demanding change.

Why Excedrin embraced the headache of a contentious election season

Why Excedrin embraced the headache of a contentious election season

By

Excedrin's #DebateHeadache was inspired by complaints the brand noticed during the first presidential debate in September.

Is This the End of Agency Diversification?

Is This the End of Agency Diversification?

By

DTC and OTC/wellness can borrow from mainstream consumer shops. Professional marketing may pose a tougher sell.

Langland's Andrew Spurgeon on Simplicity in Ads

Langland's Andrew Spurgeon on Simplicity in Ads

Spurgeon on finding simplicity in Procter & Gamble's "The Boy Raised by Goats" and a moving campaign about disabilities.

Five things for pharma marketers to know: Thursday, December 31, 2015

Five things for pharma marketers to know: Thursday, December 31, 2015

By

Generic Nexium will be blue; researcher says scientific papers should be anonymous; patients with health insurance still struggle to cover the costs of drugs

Pfizer ends bid for OTC Lipitor

Pfizer ends bid for OTC Lipitor

By

The drugmaker told investors that the actual-use trial failed to meet the primary objectives.